"Drug-Tolerant Assay Not Needed For Infliximab-Treated IBD Patients" - Marilynn Larkin
In patients in stable remission from inflammatory bowel disease (IBD) on infliximab, a drug-tolerant assay yields no benefit over a less costly drug-sensitive assay even though the latter detects more anti-drug antibodies (ADAs), researchers in Belgium say. Louis Cohen, MD, an assistant professor of gastroenterology at the Icahn School of Medicine at Mount Sinai called the study "important," noting "this study is well designed and presents an intriguing conclusion that supports the belief that the presence of antibodies in a patient sample is likely to be far more clinically meaningful when there is no infliximab present, as a potential surrogate for the neutralizing capability of the antibodies."
- Louis Cohen, MD, Assistant Professor, Medicine, Gastroenterology, Icahn School of Medicine at Mount Sinai